In the current study it is shown that treatment of CRC cells with γ-secretase inhibitors (GSI), which leads to inhibition of Notch signalling, is not sufficient to induce pronounced inhibitory effects on CRC cell proliferation or survival, but results in activation of the MAP kinases Erk1/2. The gene discussed is MAPK3; the disease is colorectal carcinoma.